Free Trial
NASDAQ:OMER

Omeros (OMER) Stock Price, News & Analysis

$3.42
+0.06 (+1.79%)
(As of 05/22/2024 ET)
Today's Range
$3.29
$3.51
50-Day Range
$3.04
$4.20
52-Week Range
$0.92
$7.80
Volume
208,478 shs
Average Volume
288,704 shs
Market Capitalization
$198.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Omeros MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
24.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.30
Upright™ Environmental Score
News Sentiment
-0.20mentions of Omeros in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.21 out of 5 stars

Medical Sector

898th out of 920 stocks

Pharmaceutical Preparations Industry

418th out of 426 stocks

OMER stock logo

About Omeros Stock (NASDAQ:OMER)

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

OMER Stock Price History

OMER Stock News Headlines

Omeros (NASDAQ:OMER) Rating Reiterated by Needham & Company LLC
Omeros Shares Drop 20% After Wider 1Q Loss
Omeros (NASDAQ:OMER) Downgraded by StockNews.com
Q1 2024 Omeros Corp Earnings Call
OMER Stock Earnings: Omeros Misses EPS for Q1 2024
Omeros Q1 2024 Earnings Preview
Omeros Shares Down 6% on Swing to 4Q Loss
Q4 2023 Omeros Corp Earnings Call
OMER Stock Earnings: Omeros Misses EPS for Q4 2023
OMER Aug 2024 3.000 put
OMER Aug 2024 5.000 put
See More Headlines
Receive OMER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/01/2024
Today
5/23/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:OMER
CUSIP
68214310
Employees
198
Year Founded
1994

Profitability

Net Income
$-117,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.23) per share

Miscellaneous

Free Float
51,628,000
Market Cap
$198.15 million
Optionable
Optionable
Beta
1.34

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Gregory A. Demopulos M.D. (Age 65)
    Co-Founder, Chairman, CEO & President
    Comp: $1.79M
  • Mr. Michael A. Jacobsen (Age 66)
    Chief Accounting Officer, VP of Finance & Treasurer
    Comp: $518.6k
  • Mr. Peter B. Cancelmo J.D. (Age 45)
    VP, General Counsel & Corporate Secretary
    Comp: $503.24k
  • Dr. Pamela Pierce Palmer M.D. (Age 61)
    Ph.D., Co-Founder
  • Dr. George A. Gaitanaris M.D. (Age 67)
    Ph.D., Chief Scientific Officer & VP of Science
  • Mr. Peter W. Williams (Age 56)
    Vice President of Human Resources
  • Dr. Catherine A. Melfi Ph.D. (Age 65)
    Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems
  • Ms. Nadia Dac (Age 54)
    VP & Chief Commercial Officer
  • Dr. Andreas Grauer M.D. (Age 63)
    VP & Chief Medical Officer

OMER Stock Analysis - Frequently Asked Questions

Should I buy or sell Omeros stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares.
View OMER analyst ratings
or view top-rated stocks.

How have OMER shares performed in 2024?

Omeros' stock was trading at $3.27 at the beginning of the year. Since then, OMER shares have increased by 4.6% and is now trading at $3.42.
View the best growth stocks for 2024 here
.

When is Omeros' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our OMER earnings forecast
.

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) announced its quarterly earnings data on Monday, April, 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter.

What guidance has Omeros issued on next quarter's earnings?

Omeros updated its first quarter 2024 earnings guidance on Monday, April, 1st. The company provided EPS guidance of -0.630--0.580 for the period. The company issued revenue guidance of -.

What is Gregory A. Demopulos' approval rating as Omeros' CEO?

17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Omeros own?
Who are Omeros' major shareholders?

Omeros' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.61%), Susquehanna Fundamental Investments LLC (0.27%), Simplex Trading LLC (0.00%), BNP Paribas Financial Markets (0.05%), Comerica Bank (0.05%) and Oppenheimer & Co. Inc. (0.04%). Insiders that own company stock include Arnold C Hanish, Gregory A Md Demopulos and Peter A Md Demopulos.
View institutional ownership trends
.

How do I buy shares of Omeros?

Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Omeros have any subsidiaries?
The following companies are subsidiares of Omeros: Nura.
Read More
This page (NASDAQ:OMER) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners